CA-VERDEZYNE/WILL-&-CO
9.6.2015 15:01:49 CEST | Business Wire | Pressemeddelelse
Verdezyne, Inc. , a privately-held industrial biotechnology company focused on producing renewable chemicals, has reached an agreement with Will & Co, a sales and marketing firm for raw materials, semi-finished products, additives, and pigments, for distribution of Verdezyne’s first commercial product. The exclusive agreement is for sales and distribution of BIOLON™ DDDA (biobased dodecanedioic acid or “DC12”) in Europe, one of the world’s largest chemical markets. BIOLON™ DDDA will be produced at Verdezyne’s commercial-scale plant in Malaysia. The agreement secures off-take for over 25% of the expected plant capacity.
Verdezyne’s BIOLON™ DDDA is produced more sustainably than traditional petroleum-derived intermediate chemicals and will be used to make engineering polymer resins, automotive parts, toothbrush bristles, cosmetics, fragrances, and more.
“This agreement with Will & Co is an important milestone for us because it reflects the strong demand for renewable chemicals and the demonstrated high quality of our product,” said E. William Radany, Ph.D., President and CEO of Verdezyne. “With a focus on serving customers, Will & Co is the perfect partner for us and we are proud to be associated with them. Having forged this mutually beneficial distribution partnership for a significant portion of our production capacity, we are even more excited to start producing BIOLON™ DDDA as soon as possible.”
Verdezyne’s plant, expected to open in 2017, is anticipated to have the capacity to produce over 10,000 metric tons of diacids annually, including BIOLON™ DDDA, drawing on Malaysia’s diverse and abundant base of plant-derived feedstocks.
“For some time, our customers have been asking us for an alternative to petroleum-derived chemicals, and Verdezyne’s BIOLON™ DDDA fits the bill perfectly,” commented Jacques van Lindonk, Managing Director at Will & Co. “We are excited to finally be able to offer them a biobased, versatile, sustainable chemical for such a wide variety of uses, at competitive prices. It is Will & Co’s focus to expand the product portfolio with biobased products, and through our cooperation with Verdezyne we take an important step forward.”
For samples, orders or more information about Verdezyne’s BIOLON ™ DDDA, please contact:
- Europe: ddda@will-co.nl
- Worldwide: ddda@verdezyne.com
About Verdezyne
Verdezyne is an industrial biotechnology company using proven and proprietary metabolic pathway engineering tools to develop unique yeast strains for cost-effective production of biobased chemicals. Current investors in Verdezyne include BP Alternative Energy Ventures, DSM Venturing B.V., OVP Venture Partners, Monitor Ventures, and Sime Darby. For more information, visit www.verdezyne.com or connect with the company on Twitter , LinkedIn or Facebook .
About Will & Co
Will & Co, established in the Netherlands in 1924, have been active in the distribution and trading of chemical raw materials ever since. During the years Will & Co has grown into an international supplier of specialty chemicals, high quality raw materials, additives and colorants. We cooperate very closely with the manufacturers of these products, mainly on the basis of exclusivity. Our experienced staff does everything to supply maximal service to our customers and business relations in the various industries. We offer a wide range of products, combined with the necessary know-how and support for production and product development. More information is available at www.will-co.nl .
View source version on businesswire.com: http://www.businesswire.com/news/home/20150609005567/en/
Contact:
Verdezyne, Inc.
Aida Yodites, 760-707-5200
Corporate
Communications
ayodites@verdezyne.com
or
Sparkpr
Bill
Douglass, 646-504-0890
bdouglass@sparkpr.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum